All News

The potential cardiovascular impact of prolonged oral corticosteroid therapy in the AD population observed in this study confirms longstanding cautions.

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.

Your daily dose of the clinical news you may have missed.

Medical and nonpharmacologic treatment options for VMS range in efficacy and risk/benefit profile; a short slide show offers a topline look at how many compare.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.

Your daily dose of the clinical news you may have missed.

The Teal Wand allows women to collect a vaginal sample in the privacy of their home and, according to Teal Health, the test has 96% accuracy for cervical precancer.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

Adults receiving the highest dose achieved 2 times the reduction in EASI scores vs placebo with responses emerging as early as day 8 of treatment.